Therapeutic potential of RNA interference against cancer
- 9 June 2006
- journal article
- review article
- Published by Wiley in Cancer Science
- Vol. 97 (8) , 689-696
- https://doi.org/10.1111/j.1349-7006.2006.00234.x
Abstract
One of the most dramatic events of the past 5 years in the field of molecular biology has been the discovery of RNA interference (RNAi). Although RNAi is an evolutionarily conserved phenomenon for sequence-specific gene silencing in mammalian cells, exogenous small interfering RNA (siRNA) and vector-based short hairpin RNA (shRNA) can also invoke RNAi responses. Both are now not only experimental tools for analyzing gene function but are expected to be excellent avenues for drug target discovery and the emerging class of gene medicine for targeting incurable diseases such as cancer. The success of cancer therapeutic use of RNAi relies on the development of safe and efficacious delivery systems that introduce siRNA and shRNA expression vectors into target tumor cells. For their delivery, a variety of strategies have been used, most of them based on traditional gene therapy delivery systems. In this review, we present siRNA delivery method strategies and discuss the potential of RNAi-based gene therapy in cancer treatment.This publication has 54 references indexed in Scilit:
- Characterization of the Bystander Effect of Somatostatin Receptor sst2 AfterIn VivoGene Transfer into Human Pancreatic Cancer CellsHuman Gene Therapy, 2005
- RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivoGene Therapy, 2004
- Systemic siRNA-Mediated Gene SilencingAnnals of Surgery, 2004
- The functions of animal microRNAsNature, 2004
- Intravenous RNA Interference Gene Therapy Targeting the Human Epidermal Growth Factor Receptor Prolongs Survival in Intracranial Brain CancerClinical Cancer Research, 2004
- Potential of Atelocollagen-Mediated Systemic Antisense Therapeutics for Inflammatory DiseaseHuman Gene Therapy, 2004
- RETRACTED ARTICLE: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinomaOncogene, 2004
- MicroRNAsCell, 2004
- Antisense oligodeoxynucleotide against HST‐1/FGF‐4 suppresses tumorigenicity of an orthotopic model for human germ cell tumor in nude miceThe Journal of Gene Medicine, 2003
- Effective expression of small interfering RNA in human cellsNature Biotechnology, 2002